Novavax (NVAX)
(Delayed Data from NSDQ)
$12.91 USD
+0.39 (3.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $12.92 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Company Summary
Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune-stimulating saponin-based adjuvants, namely Matrix-M, added to the company’s vaccines to enhance immune response.
Novavax developed its novel coronavirus vaccine, a protein-based vaccine that utilizes the company’s proprietary nanoparticle technology. The company’s COVID-19 vaccine is authorized for use in the United States in adults and adolescents aged 12 years and older. The vaccine is also approved/authorized for use in multiple markets like Australia, ...
Company Summary
Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune-stimulating saponin-based adjuvants, namely Matrix-M, added to the company’s vaccines to enhance immune response.
Novavax developed its novel coronavirus vaccine, a protein-based vaccine that utilizes the company’s proprietary nanoparticle technology. The company’s COVID-19 vaccine is authorized for use in the United States in adults and adolescents aged 12 years and older. The vaccine is also approved/authorized for use in multiple markets like Australia, Canada, Europe, India and Indonesia.
In May 2024, the company entered into a multi-billion-dollar partnership with Sanofi. Per the deal terms, Sanofi will gain rights to co-market Novavax’s COVID-19 vaccine globally, except in certain countries where Novavax has existing partnership agreements. Sanofi also has the sole license to develop and market this vaccine in combination with its influenza vaccine. The deal will be effective from Jan 1, 2025.
Novavax has developed a recombinant quadrivalent seasonal influenza vaccine candidate (formerly NanoFlu). Management is also evaluating the combination of the influenza vaccine with the COVID-19 vaccine. The company intends to advance both candidates to late-stage development before 2024-end.
To rationalize its manufacturing footprint and reduce costs, the company has undertaken multiple restructuring initiatives. These initiatives have not only helped the company in bringing down its current costs but also reduced short-term liabilities by around $800 million.
In 2023, the company generated $983.7 million in total revenues, down 50% year over year.
General Information
Novavax, Inc
700 Quince Orchard Road
GAITHERSBURG, MD 20878
Phone: 240-268-2000
Fax: 240-268-2100
Email: ir@novavax.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.91 |
Current Year EPS Consensus Estimate | -1.04 |
Estimated Long-Term EPS Growth Rate | 27.10 |
Exp Earnings Date | 11/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 12.52 |
52 Week High | 23.86 |
52 Week Low | 3.53 |
Beta | 2.04 |
20 Day Moving Average | 5,348,937.00 |
Target Price Consensus | 18.17 |
4 Week | 7.67 |
12 Week | 1.97 |
YTD | 168.96 |
4 Week | 6.39 |
12 Week | -2.35 |
YTD | 117.75 |
Shares Outstanding (millions) | 160.09 |
Market Capitalization (millions) | 2,066.81 |
Short Ratio | NA |
Last Split Date | 5/10/2019 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 70.69% |
vs. Previous Quarter | 194.29% |
vs. Previous Year | -2.11% |
vs. Previous Quarter | 342.69% |
Price/Book | NA |
Price/Cash Flow | NA |
Price / Sales | 2.09 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | -17.77 |
3/31/24 | -24.56 |
12/31/23 | -32.63 |
6/30/24 | 1.04 |
3/31/24 | 0.90 |
12/31/23 | 0.70 |
6/30/24 | 1.03 |
3/31/24 | 0.88 |
12/31/23 | 0.67 |
6/30/24 | -29.80 |
3/31/24 | -40.01 |
12/31/23 | -55.41 |
6/30/24 | -29.80 |
3/31/24 | -40.01 |
12/31/23 | -55.41 |
6/30/24 | -29.25 |
3/31/24 | -39.69 |
12/31/23 | -55.20 |
6/30/24 | -3.07 |
3/31/24 | -6.18 |
12/31/23 | -6.04 |
6/30/24 | 10.55 |
3/31/24 | 9.80 |
12/31/23 | 8.14 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |